‌

Actions

Action Type

‌
‌

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Overview

Detailed Summary

Ajanta Pharma Limited is a specialty pharmaceutical company engaged in manufacturing and marketing branded generics in India, Asia, Africa, and the U.S.
The company displays impressive performance with a 20% revenue growth this quarter, driven by strong gains in Africa and the U.S. markets, where the U.S. generics business grew by 52%.
Ajanta Pharma launched 13 new products in chronic therapies in Asia over the past months, enhancing the long-term sustainability of their business in the region.
The firm is strengthening its field force by adding 150 medical representatives and venturing into new segments like gynecology, indicating strategic investments in growth.
Ajanta's collaboration with Biocon for GLP-1 products in 26 countries enhances its future growth prospects through an exclusive arrangement that promises significant market penetration.

Sector: Pharmaceuticals
Industry: Pharmaceuticals - Indian - Formulations
Market Cap: 36,468 Cr
Volatility: Low Risk
P/E Ratio: 35.9
Industry P/E: 43.7
PEG Ratio: 3.3
P/B Ratio: 8.5
52W High: 3,020.45
52W Low: 2,022.05

Sales CAGR

1Y: 10.44%
3Y: 11.23%
5Y: 14.50%
10Y: 11.88%

Profit CAGR

1Y: 12.77%
3Y: 8.40%
5Y: 15.76%
10Y: 9.01%

ROE

TTM: 22.56%
3Y: 21.63%
5Y: 21.71%
10Y: 22.24%

ROCE

TTM: 27.85%
3Y: 27.27%
5Y: 27.52%
10Y: 28.53%

Technicals

‌

Forecasts

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Upgrade

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
AJANTPHARM	2913.00	36,468 Cr	35.87	8.45	0.96	22.56	27.85	17.89
GLAND	1779.65	29,321 Cr	33.93	3.07	1.01	8.27	12.46	7.18
ERIS	1414.65	19,596 Cr	47.12	5.58	0.51	13.45	14.38	6.57
SAILIFE	915.95	19,340 Cr	57.03	8.52	0.00	12.62	16.34	9.99
CAPLIPOINT	1729.65	13,171 Cr	21.42	4.17	0.35	18.64	23.29	17.76
RUBICON	783.40	12,916 Cr	62.57	11.25	0.00	26.49	22.49	11.57
MARKSANS	182.00	8,232 Cr	22.89	3.06	0.44	13.08	16.13	10.51

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	1,028	1,105	1,054	1,145	1,187	1,146	1,170	1,303	1,354	1,375
Expenses	738	791	776	815	875	825	873	951	1,026	993
Operating Profit	291	314	278	330	311	321	297	351	328	382
OPM %	28.26	28.42	26.40	28.85	26.22	27.99	25.39	26.97	24.22	27.80
Other Income	21	14	36	26	19	30	18	26	59	25
Interest	2.34	2.49	1.53	0.73	6.02	7.91	6.07	5.26	3.39	5.10
Depreciation	34	34	34	34	34	36	40	41	43	44
Profit Before Tax	276	291	278	322	290	307	269	331	341	359
Tax %	29.22	27.80	27.09	23.70	25.41	24.24	16.39	22.89	23.66	23.66
Net Profit	195	210	203	246	216	233	225	255	260	274
EPS in Rs	15.62	16.80	16.22	19.52	17.26	18.59	18.00	20.43	20.82	21.91

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	2,002	2,131	2,055	2,588	2,890	3,341	3,743	4,209	4,648	4,806
Expenses	1,296	1,467	1,489	1,905	1,891	2,412	2,959	3,037	3,389	3,525
Operating Profit	705	663	566	683	999	929	783	1,172	1,260	1,281
OPM %	35.23	31.14	27.56	26.41	34.56	27.82	20.93	27.85	27.10	26.64
Other Income	24	24	21	88	26	116	99	85	95	94
Interest	1.36	0.41	1.16	12	8.27	10	5.84	7.21	21	25
Depreciation	61	60	72	96	116	125	131	135	144	151
Profit Before Tax	648	623	514	664	900	909	745	1,114	1,189	1,198
Tax %	21.81	24.72	24.75	29.56	27.36	21.64	21.10	26.73	22.60	22.38
Net Profit	507	469	387	468	654	713	588	816	920	930
EPS in Rs	40.56	37.51	30.92	37.43	52.32	51.82	47.06	65.30	73.36	81.15
Dividend Payout %	22.58	0.00	20.47	24.25	12.65	17.29	15.25	78.74	38.08	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	18	18	18	18	18	17	17	25	25	25
Reserves	1,154	1,550	2,024	2,228	2,581	2,978	3,247	3,363	3,542	3,765
Borrowings	73	1.04	1.01	34	73	31	25	36	35	47
Other Liabilities	237	279	406	417	647	752	766	1,255	1,036	1,177
Total Liabilities	1,481	1,848	2,449	2,696	3,319	3,779	4,056	4,679	4,638	5,015
Fixed Assets	452	589	1,053	1,168	1,463	1,532	1,504	1,496	1,479	1,762
CWIP	240	339	61	262	132	108	153	209	256	176
Investments	66	182	190	88	89	185	155	535	349	464
Other Assets	724	738	1,145	1,179	1,635	1,954	2,244	2,438	2,554	2,613
Total Assets	1,481	1,848	2,449	2,696	3,319	3,779	4,056	4,679	4,638	5,015

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	326	609	281	375	457	576	562	792	785	1,157
Cash from Investing Activity	-209	-383	-256	-223	-224	-282	-74	-560	65	-377
Cash from Financing Activity	-119	-202	-0.20	-147	-129	-318	-460	-108	-1,051	-733
Net Cash Flow	-1.48	24	25	4.27	104	-24	28	124	-201	47

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Apr 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	66.21%	66.21%	66.21%	66.21%	66.21%	66.27%	66.26%	66.26%	66.26%	66.26%	66.25%	66.25%
FIIs	10.03%	10.19%	9.99%	9.11%	8.54%	8.36%	9.11%	9.26%	8.86%	8.86%	8.53%	7.98%
DIIs	16.02%	15.81%	15.59%	16.68%	17.49%	17.42%	17.11%	17.03%	17.49%	17.51%	17.91%	18.59%
Public	7.74%	7.78%	8.20%	8.01%	7.76%	7.94%	7.52%	7.45%	7.39%	7.38%	7.32%	7.19%
Total Shareholders	56,939	54,874	56,277	54,351	55,488	70,316	64,315	66,896	70,827	68,882	67,785	65,409

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Upgrade

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Upgrade

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q1 FY25

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q3 FY24

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q3 FY23

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q3 FY20

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q2 FY20

Showing 1 - 8 of 23

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Press Release

5 days ago

Clarification on Market Rumour

Ajanta Pharma Limited clarifies that it is not involved in any acquisition of Restaurant Brands Asia, countering a news article's claims.

AI Mode

Ask AI

Frequently Asked Questions about Ajanta Pharma Ltd

Ajanta Pharma Ltd (AJANTPHARM) is currently trading at 2,913.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Ajanta Pharma Limited is a specialty pharmaceutical company engaged in manufacturing and marketing branded generics in India, Asia, Africa, and the U.S. The company displays impressive performance with a 20% revenue growth this quarter, driven by strong gains in Africa and the U.S. markets, where the U.S. generics business grew by 52%. Ajanta Pharma launched 13 new products in chronic therapies in Asia over the past months, enhancing the long-term sustainability of their business in the region. The firm is strengthening its field force by adding 150 medical representatives and venturing into new segments like gynecology, indicating strategic investments in growth. Ajanta's collaboration with Biocon for GLP-1 products in 26 countries enhances its future growth prospects through an exclusive arrangement that promises significant market penetration.

Over the past 52 weeks, Ajanta Pharma Ltd has traded between a low of ₹2,022.05 and a high of ₹3,020.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Ajanta Pharma Ltd has a market capitalization of approximately 36,468.08. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Ajanta Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 35.87 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 36,468.08 Cr, Ajanta Pharma Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Ajanta Pharma Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Ajanta Pharma Ltd is 35.87. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The 'Biopharma Shakti' initiative is the most significant announcement. With a ₹10,000 crore outlay, it aims to make India a global biopharma hub, supporting Ajanta's long-term strategy to move into higher-value products like biologics and biosimilars.

Ajanta Pharma Ltd

Actions

AI Mode

Ask AI

Utility

Company

Overview

Financial Ratios

Technicals

Forecasts

Unlock Premium Features

Upgrade

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Unlock Premium Features

Upgrade

Projection

Unlock Premium Features

Upgrade

Documents

Actions

Announcements

Clarification on Market Rumour

AI Mode

Ask AI

Frequently Asked Questions about Ajanta Pharma Ltd

What is Ajanta Pharma Ltd share price today?

What does Ajanta Pharma Ltd do?

What is the 52-week high and low of Ajanta Pharma Ltd?

What is the market capitalization of Ajanta Pharma Ltd?

Should I consider investing in Ajanta Pharma Ltd stock?

Is Ajanta Pharma Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Ajanta Pharma Ltd belong to and why does it matter?

What is the PE ratio of Ajanta Pharma Ltd?

What is the most significant announcement in Union Budget 2026 for Ajanta Pharma?

Technicals

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Shareholdings

Shareholding History

Market Transactions

Unlock Premium Features

Upgrade

Projection

Unlock Premium Features

Upgrade

Documents

Frequently Asked Questions about Ajanta Pharma Ltd

What is Ajanta Pharma Ltd share price today?

What does Ajanta Pharma Ltd do?

What is the 52-week high and low of Ajanta Pharma Ltd?

What is the market capitalization of Ajanta Pharma Ltd?

Should I consider investing in Ajanta Pharma Ltd stock?

Is Ajanta Pharma Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Ajanta Pharma Ltd belong to and why does it matter?

What is the PE ratio of Ajanta Pharma Ltd?

What is the most significant announcement in Union Budget 2026 for Ajanta Pharma?

Oscillators

Neutral

Overall

Bullish

Moving Averages

Bullish

Overall

Bullish

Forecasts

Unlock Premium Features